AI-researched · adversarially reviewed · human-checked · corrections public
BEFORE YOU READ — HOW DO YOU RULE?
The Verdict
For people with type 2 diabetes, and for people with obesity plus heart-disease risk, GLP-1 drugs are the real thing: roughly 15–20% body-weight loss in trials and — rare for any weight drug — proven reductions in heart attacks and strokes. The catches are just as real: gastrointestinal misery for many, muscle inside the lost weight, most of the weight returning when you stop, a price built for shareholders, and a market now stretching the drug far beyond the people it was tested on.
strongProduces large weight loss in people with obesity: semaglutide averaged ~15% of body weight over 68 weeks; tirzepatide ~20% — levels previously seen only with surgery.
strongReduces heart attacks and strokes in people with obesity and existing cardiovascular disease (SELECT trial) — the first weight drug ever to show this.
strongControls blood sugar in type 2 diabetes; that was its original, well-proven job.
moderateLikely slows kidney-disease progression in diabetics at risk (FLOW trial stopped early for benefit).
weakMay reduce alcohol craving and other compulsive consumption — early trials are intriguing and unfinished.
§ What it doesn't do
Where the marketing outruns the data
strongDoes not cure anything: stop the drug and most of the weight returns — participants regained roughly two-thirds of lost weight within a year of stopping. The honest model is a chronic treatment, priced like a subscription to your own body.
moderateDoes not make the lost weight all fat: a meaningful fraction is lean mass/muscle — a real concern for older users, and the reason resistance training and protein matter alongside it.
noneThere is no trial evidence for the cosmetic last-5-kg user — the trials enrolled people with obesity or diabetes, not people chasing a wedding dress size.
contradicted"Well tolerated" marketing understates reality: nausea, vomiting, constipation and diarrhea are very common; a substantial minority quit because of them.
§ The Money Map
Who profits, stage by stage
The manufacturersNovo Nordisk and Eli Lilly earn tens of billions per year from GLP-1s; Novo became Europe's most valuable company on the back of semaglutide. Every landmark trial here was manufacturer-funded (COI-flagged below) — rigorously run and FDA-audited, but the funding line belongs in view.
The priceUS list price roughly $1,000/month; the same pens sell for a fraction of that in Europe and India. The price is what the market bears, not what production costs.
The prescribing boomTelehealth mills prescribe after a questionnaire; med-spas and compounding pharmacies sell "semaglutide" of variable provenance in a regulatory gray zone the FDA keeps warning about.
The influencersCelebrity before/afters and #Ozempic content sell the cosmetic use the trials never tested — no one in that pipeline is paid to mention muscle loss or regain.
This pageNo pharma money, no telehealth affiliate links, no supplement "alternatives" for sale. See "How we make money."
§ The other side
The strongest case against this verdict
The strongest case for deeper skepticism than our verdict: these drugs are a decade old at population scale, and we are medicating the food environment instead of fixing it. Long-term effects of chronic GLP-1 use across tens of millions of healthy-ish people are simply unknown — rodent thyroid tumors, rare pancreatitis and gastroparesis signals, and the lean-mass question deserve more respect than the gold-rush is giving them. The regain data means we may be enrolling a generation into a $12,000-a-year dependency whose exit door leads back to the starting weight. A society that needed an injection to survive its own food supply has treated a symptom and called it a cure.
§ Symmetric harms
Harms of using it — and of avoiding it
If you use it
Very common GI effects (nausea, vomiting, constipation); a meaningful minority discontinue because of them.
Rare but real: pancreatitis, gastroparesis (now in litigation), gallbladder disease; rapid weight loss itself raises gallstone risk.
Muscle loss within the lost weight — worst deal for older adults.
The exit problem: stopping usually means regaining; few users are told this at the point of prescription.
Financial: at US prices, years of use costs more than most cars.
If you avoid it
For type 2 diabetics and people with obesity + heart disease: refusing a drug with proven cardiovascular benefit leaves real, countable risk on the table.
For people with severe obesity: the "just diet" alternative has a decades-long documented failure rate; moralizing it has saved no one.
§ The Minority Report
Who gets hurt when it goes right for everyone else
The harms concentrate in identifiable groups — mostly people the trials never enrolled.
People with a personal/family history of medullary thyroid carcinoma or MEN2: formally contraindicated (rodent tumor signal).
People with a history of pancreatitis or gastroparesis: the rare severe GI outcomes cluster here.
Older adults and the already-lean: muscle loss hits hardest where reserve is lowest.
People with eating disorders: questionnaire-based telehealth happily supplies a powerful appetite suppressant to exactly the people it can hurt most.
Cosmetic users buying gray-market "compounded semaglutide": dosing errors and unverified vials — the FDA has logged hundreds of adverse-event reports.
How to tell if you might be in this group: Ask: do the trial populations include someone like me (BMI, diabetes, heart risk)? Any thyroid-cancer family history? Any pancreatitis? Am I prepared for the exit problem — what is my plan for the day I stop?
§ The alternatives ledger
Everything else, judged by the same standards
strong
Bariatric surgery Still the heavyweight: larger, more durable weight loss and long-term mortality benefit in observational data. More invasive, more upfront risk.
moderate
Structured diet + resistance training Average results are modest and regain is common — but it is the only option that adds muscle instead of subtracting it, and it compounds with everything else.
strong
Metformin and older diabetes drugs For glucose control: cheap, proven, decades of safety data. Not a weight-loss tool of this magnitude.
none
"Natural Ozempic" (berberine et al.) There is no evidence that any supplement replicates GLP-1 effects, despite an entire TikTok economy claiming otherwise.
§ The AI Showdown
What other AIs tell you when you ask
We asked each AI the plain question a normal person types: “Does Ozempic actually work for weight loss, and what are the side effects?”
ChatGPT
gpt-5.5 · Oct 11, 2026
6/10
A clinically solid, well-organized safety rundown that lands close to the evidence on efficacy and regain but understates the cardiovascular benefit and muscle loss and ignores the money and marketing forces driving this drug.
●○Matches the evidence. It correctly says semaglutide produces large weight loss (~10–15%) and that weight returns after stopping, but it omits the proven cardiovascular benefit (SELECT) and the muscle/lean-mass loss, and its figure sits slightly below the ~15% trial average.
●●Names the harms. It lists the common GI effects, the serious ones (pancreatitis, gallbladder, kidney, retinopathy, hypoglycemia), the thyroid C-cell warning, and names groups who should avoid it — missing only muscle loss and eating-disorder/compounded-product risk.
○○Follows the money. It says nothing about manufacturer funding of the trials, the ~$1,000/month US price, telehealth prescribing, or compounded semaglutide.
●○Honest about uncertainty. It gives a range, notes 'some lose more, some less' and dose-relatedness, but offers no caveat about who the trials enrolled, long-term unknowns, or how often people quit from side effects.
●●Useful next step. It repeatedly directs the reader to a clinician, flags conditions worth raising, and suggests asking whether Wegovy or another approved option fits, without diagnosing or telling anyone to start or stop anything.
Read its full answer
Yes. **Ozempic can lead to significant weight loss**, although it’s officially approved for **type 2 diabetes**, not weight loss. The same active ingredient, **semaglutide**, is approved specifically for chronic weight management under the brand name **Wegovy** at a higher target dose.
## How well does it work?
Semaglutide mimics a gut hormone called **GLP-1**, which helps you feel full sooner, reduces appetite, slows stomach emptying, and improves blood sugar control.
In clinical studies of semaglutide for obesity/overweight, many people lost roughly **10–15% of their body weight** on average when combined with diet and activity changes. Some lose more, some less. Weight loss usually builds gradually over months.
A key point: **weight often comes back after stopping** unless long-term lifestyle changes and/or ongoing medication are maintained.
## Common side effects
The most common side effects are digestive, especially when starting or increasing the dose:
- **Nausea**
- **Vomiting**
- **Diarrhea**
- **Constipation**
- **Stomach pain/bloating**
- **Heartburn or indigestion**
- Reduced appetite, sometimes to an uncomfortable degree
These are often dose-related and may improve over time.
## Less common but serious risks
You should discuss risks with a clinician, especially if you have other medical conditions. Potential serious side effects include:
- **Pancreatitis**: severe abdominal pain, often radiating to the back, with nausea/vomiting
- **Gallbladder problems**: gallstones or inflammation, especially with rapid weight loss
- **Kidney problems**: usually related to dehydration from vomiting/diarrhea
- **Low blood sugar**, mainly if used with insulin or sulfonylurea diabetes meds
- **Worsening diabetic retinopathy** in some people with diabetes, particularly with rapid glucose improvement
- Rare allergic reactions
Semaglutide carries a warning about **thyroid C-cell tumors** seen in rodents. It’s generally avoided in people with a personal/family history of **medullary thyroid cancer** or **MEN2 syndrome**.
## Who should be careful or avoid it?
It may not be appropriate if you are pregnant, trying to become pregnant, breastfeeding, have a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, or certain thyroid cancer syndromes.
## Bottom line
Ozempic/semaglutide **does work for weight loss for many people**, but it’s not risk-free and should be used under medical supervision, ideally as part of a longer-term plan for nutrition, activity, and weight maintenance. If weight loss is the main goal, ask your clinician whether **Wegovy** or another FDA-approved weight-loss medication is more appropriate.
Gemini
gemini-3.8-flash · Oct 11, 2026
5/10
A clear, largely accurate clinical rundown with strong harm coverage, weakened by a universal rather than conditional verdict, a missing cardiovascular-benefit finding, no sourcing or follow-the-money context, and only a generic "see a doctor" ending.
●○Matches the evidence. Gets the ~15% over 68 weeks and the two-thirds regain right, but states a universal "works very effectively" rather than a for-whom verdict and omits the proven cardiovascular benefit (SELECT) that is central to the evidence.
●●Names the harms. Covers common GI effects, muscle loss, pancreatitis, gallbladder disease, gastroparesis, kidney injury and the MTC/MEN2 contraindication, matching the evidence in proportion.
○○Follows the money. Says nothing about manufacturer funding of the trials, the ~$1,000/month US price, telehealth/compounding sellers, or influencer marketing.
●○Honest about uncertainty. Gives averages and flags rare risks, but offers an unsourced "25–40%" muscle-loss figure and no named sources, and does not note that trials enrolled people with obesity or diabetes rather than cosmetic users.
●○Useful next step. Tells the reader to discuss medical history with a doctor but supplies no specific questions to ask, such as thyroid-cancer family history or a plan for stopping.
Read its full answer
**Yes, Ozempic works very effectively for weight loss.**
However, to understand how it works and what to expect, it helps to understand what the medication actually is and how it affects the body.
Here is a breakdown of how it works, how effective it is, and its potential side effects.
---
### Does It Work for Weight Loss?
**Yes.** The active ingredient in Ozempic is **semaglutide**. While Ozempic is technically FDA-approved to treat Type 2 diabetes, doctors frequently prescribe it "off-label" for weight loss. (A higher-dose version of semaglutide, marketed under the brand name **Wegovy**, is officially FDA-approved specifically for chronic weight management.)
#### How it works:
Semaglutide is a **GLP-1 receptor agonist**. It mimics a natural hormone your body produces when you eat, which does three main things:
1. **Slows stomach emptying:** Food stays in your stomach longer, making you feel full faster and for longer periods.
2. **Targets the brain:** It signals to the brain's appetite center that you are satisfied, drastically reducing cravings and what many people call "food noise" (constant thoughts about food).
3. **Regulates blood sugar:** It prompts the pancreas to release insulin when blood sugar is high.
#### How much weight do people lose?
In major clinical trials (such as the STEP trials):
* People taking therapeutic doses of semaglutide lost an **average of 15% of their body weight** over 68 weeks when combined with diet and exercise.
* For a 200-pound person, that is an average loss of about 30 pounds.
#### The Catch:
* **It is not a quick fix:** The weight loss only continues while taking the medication. Studies show that when people stop taking semaglutide, they typically regain two-thirds of the lost weight within a year.
* **Lifestyle still matters:** It works best alongside a healthy diet and resistance training (to prevent muscle loss).
---
### What Are the Side Effects?
Because the drug directly impacts your digestive system, the vast majority of side effects are gastrointestinal. These usually occur when you first start the medication or when you increase your dose.
#### 1. Common Side Effects (Affecting roughly 1 in 10 people or more)
* **Nausea:** By far the most common side effect.
* **Vomiting**
* **Diarrhea or Constipation:** Constipation can become severe if not managed with hydration and fiber.
* **Stomach pain and bloating**
* **Acid reflux / Heartburn**
* **"Sulfur burps":** Burps that smell or taste like rotten eggs due to food sitting in the stomach longer.
* **Fatigue and headaches**
#### 2. Cosmetic and Body Composition Side Effects
* **Muscle Loss:** When people lose weight rapidly, up to 25–40% of the weight lost can be lean muscle mass rather than fat. Strength training and high protein intake are recommended to counter this.
* **"Ozempic Face":** A colloquial term for sagging skin or a hollow look in the face, which is simply the natural result of rapid facial fat loss.
#### 3. Serious (Rare) Risks
These are uncommon, but they require immediate medical attention:
* **Pancreatitis:** Severe inflammation of the pancreas, causing unbearable abdominal pain that radiates to the back.
* **Gallbladder issues:** Rapid weight loss increases the risk of gallstones or gallbladder inflammation (cholecystitis).
* **Gastroparesis (Stomach Paralysis):** In rare cases, the stomach slows down too much or stops moving food entirely.
* **Kidney Injury:** Often caused secondarily by severe dehydration from prolonged vomiting or diarrhea.
* **Thyroid C-Cell Tumors:** In rodent studies, semaglutide caused thyroid tumors. It has a "black box warning" and is contraindicated for people with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
---
### The Bottom Line
Ozempic is one of the most effective medical treatments for obesity ever developed, but it is a serious, long-term medication, not a casual diet pill. Anyone considering it should discuss their medical history with a doctor to weigh the benefits against the potential side effects.
Claude
claude-opus-5 · Oct 11, 2026
7/10
A clear, well-calibrated and unusually complete rundown of benefits and harms that falls short mainly by skipping the proven cardiovascular benefit, the industry funding behind the evidence, and specific questions for a clinician.
●○Matches the evidence. Correctly reports ~15% loss in STEP 1, tirzepatide ~20%, and the two-thirds regain after stopping, but omits the landmark proven cardiovascular benefit (SELECT) and the absence of trial evidence for cosmetic/low-BMI users.
●●Names the harms. Lists GI effects and discontinuation, pancreatitis, gallbladder, gastroparesis/obstruction, hypoglycemia, anesthesia aspiration, thyroid contraindication (MTC/MEN2), muscle loss and the eye signal — closely matching the evidence.
●○Follows the money. Mentions US list price over $1,000/month and insurance barriers but says nothing about manufacturer funding of the trials, telehealth/compounding sellers, or marketing pressure.
●●Honest about uncertainty. Uses conditional ranges (6–10% in diabetes, ~5–7% discontinuation), flags rodent-only tumor data, unresolved NAION signal, no established suicidality link, and its own knowledge cutoff.
●○Useful next step. Directs the reader to a doctor and gives a few concrete actions (tell the anesthesiologist, seek care for severe abdominal pain) but offers no real list of questions to ask before starting.
Read its full answer
## Does it work?
Yes — the evidence is strong. Semaglutide (the drug in Ozempic) is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying.
**Key trial data:**
- In the STEP 1 trial, people on semaglutide 2.4 mg weekly lost about **15% of body weight** over 68 weeks, vs. ~2.4% on placebo. Roughly a third lost 20% or more.
- That's substantially more than older weight-loss drugs, and approaches what some bariatric surgeries achieve.
- Results are more modest in people with type 2 diabetes (~6-10%), for reasons that aren't fully understood.
**A naming note:** Ozempic is approved for type 2 diabetes. **Wegovy** is the same molecule at a higher dose, approved specifically for weight management. Ozempic is often prescribed off-label for weight loss. Tirzepatide (Mounjaro/Zepbound) appears somewhat more effective still, with ~20% average loss.
**Important caveat:** weight tends to come back after stopping. In extension studies, people regained roughly two-thirds of lost weight within a year of discontinuing. These are generally framed as long-term medications, like blood pressure drugs.
## Side effects
**Common (most people experience some):**
- Nausea, vomiting, diarrhea, constipation, abdominal pain, burping
- Usually worst during dose escalation and often improve over weeks
- GI effects cause ~5-7% of people to quit in trials
**Less common but serious:**
- **Gallbladder problems** (gallstones, inflammation) — partly from rapid weight loss itself
- **Pancreatitis** — rare, but stop and seek care for severe persistent abdominal pain
- **Bowel obstruction / severe gastroparesis** — added to labeling after post-market reports
- **Hypoglycemia** — mainly if combined with insulin or sulfonylureas
- **Aspiration risk under anesthesia** — tell your surgeon/anesthesiologist; many recommend pausing before procedures
- **Boxed warning** for thyroid C-cell tumors (seen in rodents; human relevance unclear). Contraindicated if you or a family member have had medullary thyroid carcinoma or MEN2.
- **Possible eye risks** — a signal for NAION (a rare optic nerve condition) has been investigated; also worsening of diabetic retinopathy with rapid glucose drops
**Other things people notice:**
- **Muscle loss** — a meaningful fraction of weight lost is lean mass. Resistance training and adequate protein matter here, especially for older adults.
- "Ozempic face" — facial volume loss, cosmetic
- Hair thinning, usually temporary and related to rapid weight loss
- Earlier concerns about suicidality were investigated by FDA and EMA; no causal link was established
## Practical considerations
It's a weekly self-injection. Cost has been a major barrier in the US (list prices around $1,000+/month), though insurance coverage, manufacturer programs, and pricing arrangements have been shifting.
My information has a cutoff, so check current guidance — this is a fast-moving area. And this is general information, not medical advice: whether it makes sense for you depends on your health history, other medications, and goals, which is a conversation for your doctor.
Each answer is scored blind against this verdict on five public criteria (2 points each): matches the evidence, names the harms, follows the money, honest about uncertainty, useful next step. The scorer is health.ai's pipeline, which runs on Claude — also a contestant here — so the full answers are shown and a person checks every score before it goes live. Think a score is wrong? Challenge it. AI answers change over time; each card shows the date it was asked. See the full leaderboard →
§ Take it to a human
Questions for your doctor
Do I match the populations in the trials — or am I a cosmetic user extrapolating?
What is the plan for muscle: protein target and resistance training alongside the drug?
What is the exit strategy — do we taper, and what happens to my weight and my budget in year 3?
Given my history (thyroid, pancreas, gut), am I in any of the excluded groups?
Effects of 10–20 years of continuous use in non-diabetic populations.
Whether the alcohol/compulsion findings hold up in large trials.
What fraction of real-world users keep the cardiovascular benefit seen in trial-adherent patients.
§ Corrections
Updates & corrections — public, dated, proud
No corrections yet. Found an error? Challenge it — substantiated challenges are corrected within 48 hours and logged here permanently. Submit a challenge →
§ We dissect ourselves too
How WE make money
This pageNothing on this page: no pharma advertising, no telehealth referral fees, no supplement affiliates. Health.AI earns from optional Pro subscriptions to its AI tools. If that changes, this box changes first.
Demand the next dissection
Any disease, drug, supplement, or practice. The queue decides what we dissect next.